Related Experiment Video
Updated: Dec 5, 2025
A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
Published on: November 3, 2016
A Novel System for Spinal Muscular Atrophy Screening in Newborns: Japanese Pilot Study.
Masakazu Shinohara1, Emma Tabe Eko Niba1, Yogik Onky Silvana Wijaya1
1Department of Community Medicine and Social Healthcare Science, Division of Epidemiology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan; mashino@med.kobe-u.ac.jp (M.S.); niba@med.kobe-u.ac.jp (E.T.E.N.); yogik.onky@gmail.com (Y.O.S.W.); itakayam@med.kobe-u.ac.jp (I.T.).
A new system accurately detects Spinal Muscular Atrophy (SMA) using dried blood spots, enabling reliable newborn screening for early intervention with treatments like nusinersen.
Area of Science:
- Genetics and Molecular Biology
- Neurology
- Biotechnology
Background:
- Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disorder caused by SMN1 gene defects.
- Early diagnosis and treatment, such as with nusinersen, significantly improve patient outcomes.
- Newborn screening is crucial for timely intervention to alter SMA's disease trajectory.
Purpose of the Study:
- To validate a novel system for detecting SMN1 deletion using dried blood spots (DBS).
- To assess the system's accuracy for Spinal Muscular Atrophy newborn screening.
- To evaluate the feasibility of implementing this system in a large-scale screening program.
Main Methods:
- Developed a two-step detection system: direct PCR for SMN gene pre-amplification followed by real-time mCOP-PCR for SMN1 deletion analysis.
- Validated the system using DBS from 50 SMA patients and 50 controls.
- Conducted a prospective screening of 4157 Japanese newborns using DBS.
Main Results:
- The validated system demonstrated perfect sensitivity (1.00) and specificity (1.00) compared to fresh blood PCR analysis.
- Prospective screening of 4157 newborns yielded no false negatives or screening failures.
- The system proved reliable for detecting SMN1 deletions in DBS samples.
Conclusions:
- The novel DBS-based system is highly accurate and reliable for Spinal Muscular Atrophy newborn screening.
- This validated system supports the implementation of early detection programs for SMA.
- Early identification through newborn screening facilitates timely treatment and improves prognosis for SMA patients.
